Made available in DSpace on 2015-04-14T13:35:37Z (GMT). No. of bitstreams: 1 445040.pdf: 2039522 bytes, checksum: 2f433c611b99e5b28cbd56ef7aed5bb1 (MD5) Previous issue date: 2010-09-30 / Rationale: Comorbidity between difficult-to-treat epilepsies and ADHD is high, but because of concerns with the use of stimulants in this population, there is no data on the possible impact of such treatment.Objective: We studied the effect of methylphenidate in the quality of life of children and adolescents with DSM-IV criteria for ADHD and difficult-to-treat epilepsies.Methods: Open label, non-controlled trial, with intention-to-treat analysis following 30 patients for 6 months. Subjects received methylphenidate following 3 months of baseline, during which antiepileptic drugs (AEDs) were adjusted and epilepsy, ADHD and quality of life variables were assessed. Multivariate regression analysis identified the main variables correlated with outcome.Results: Only one patient withdrew because of seizure worsening. Following methylphenidate introduction, reaching doses of 0.40 - 0.50 mg/kg/day, a marked improvement in quality of life scores and a significant reduction in seizure frequency and severity were observed. Female sex, reduction of core ADHD symptom burden and tolerability to adequate doses of methylphenidate correlated with quality of life scores.Conclusion: These preliminary data suggest that methylphenidate treatment is safe and effective to patients with ADHD and difficult-to-treat epilepsies and has a positive impact on quality of life scores / Fundamentos - A associa??o entre epilepsia e TDAH ? altamente prevalente comprometendo a Qualidade de Vida de crian?as e adolescentes com crises epil?pticas. Metilfenidato Ritalina(R) - ? o medicamento de uso consagrado para o Transtorno de D?ficit de Aten??o/Hiperatividade com 80% de efic?cia em crian?as com TDAH com ou sem epilepsia. Questiona-se a possibilidade do MFD diminuir o limiar convulsivo dos pacientes epil?pticos.Objetivos - Avaliar a influ?ncia do uso de Metilfenidato sobre a Qualidade de Vida e o perfil das crises epil?pticas em crian?as e adolescentes com epilepsias de dif?cil controle.Pacientes e M?todos - Foi realizado um ensaio cl?nico aberto, n?o randomizado, com 30 crian?as e adolescentes do Ambulat?rio de Neuro-Epilepsias Graves apresentando crises de dif?cil controle e TDAH. Foram avaliadas quanto ? Qualidade de Vida, sintomas de TDAH e perfil das crises antes e ap?s o uso de MFD. Houve um ajuste/troca de FAE somente no tempo -3 (baseline). Metilfenidato foi iniciado ap?s estes 3 meses (T 0) sem outras modifica??es nos FAE com avalia??es 1 m?s e 3 meses ap?s. Foram avaliados tamb?m eventos adversos ao uso do MFD.Resultados - Ocorreu melhora da QV em todos os momentos avaliados: T -3 (baseline) a T0, T0 a T+1 e T+1 a T+3. A melhora ocorrida entre T-3 e T0, momento em que foi realizado o ajuste de FAE, n?o foi estatisticamente significativa. Nos tempos subseq?entes, com o uso de MFD, as varia??es de QV ocorridas apresentaram signific?ncia estat?stica. Ocorreu melhora da qualidade de vida com signific?ncia estat?stica em indiv?duos do sexo feminino, os que apresentaram in?cio mais tardio da doen?a e naqueles em houve maior diminui??o dos escores de d?ficit de aten??o. Os pacientes com crises generalizadas apresentaram piores ?ndices de QV. N?o houve associa??o estatisticamente significativa entre a varia??o da QV com a freq??ncia e/ou gravidade das crises, idade, dura??o da doen?a, QI, ocorr?ncia de eventos adversos.Conclus?es - Houve melhora da QV de pacientes epil?pticos de dif?cil controle tratados com MFD sem que houvesse piora na freq??ncia ou gravidade das crises. Condizente com a literatura tamb?m n?o verificamos a presen?a de efeitos colaterais de gravidade significativa ao MFD. Estes dados preliminares sugerem a possibilidade da utiliza??o deste f?rmaco no tratamento de crian?as e adolescentes com crises epil?pticas de dif?cil controle com a conseq?ente melhora de QV destes pacientes.

Submitted by Automa??o e Estat?stica (sst@bczm.ufrn.br) on 2016-01-04T19:56:36Z No. of bitstreams: 1 AndreaLucianaAraujoDaCunha_TESE.pdf: 62271689 bytes, checksum: f3e505d6758068c74606405cf05b2b9c (MD5) / Approved for entry into archive by Arlan Eloi Leite Silva (eloihistoriador@yahoo.com.br) on 2016-01-05T19:52:34Z (GMT) No. of bitstreams: 1 AndreaLucianaAraujoDaCunha_TESE.pdf: 62271689 bytes, checksum: f3e505d6758068c74606405cf05b2b9c (MD5) / Made available in DSpace on 2016-01-05T19:52:34Z (GMT). No. of bitstreams: 1 AndreaLucianaAraujoDaCunha_TESE.pdf: 62271689 bytes, checksum: f3e505d6758068c74606405cf05b2b9c (MD5) Previous issue date: 2013-08-30 / Despite the advances in the cure rate for acute myeloid leukemia, a considerable number of patients die from their disease due to the occurrence of multidrug resistance (MDR). Overexpression of the transporter proteins P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) confer resistance to the treatment these leukemias. OBJECTIVE: To analyze the expression of the Gpp and MRP1 in patients with AML by flow cytometry (FC) and to determine the correlation between expression and demographic and also clinical and laboratorial variables. METHODS: Bone marrow and peripheral blood samples from 346 patients with a diagnosis of AML were assessed for the expression of Pgp and MRP1 by FC. RESULTS: The expression of Pgp and MRP1 was found in 111 (32.1%) and 133 (38.4%) patients, respectively, with greater prevalence in older patients and lower in adolescents, observing also a high incidence in patients with refractory disease, recurrence and secondary in comparison with the cases of de novo AML. Regarding the laboratory findings, we observed a higher correlation statistically significant between the expression of Pgp and MRP1 in AML CD34+ and FAB AML M7, M5A and M2 and lower the M3 subtype, not observed statistically significant correlation between the phenotype MDR and other laboratory data such with hemoglobin, leukocyte count, platelet count, aberrant expression of lymphoid antigens (CD2, CD7 and CD19) and clinical signs related to the disease. CONCLUSIONS: The results showed that the detection of MDR phenotype by flow cytometry can be a molecular marker for prognosis independent patients diagnosed with AML.